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Abstract
Purpose Pseudoprogression is a rare complication of radia-
tion therapy, and discrimination between true progression
and pseudoprogression is of paramount importance for fur-
ther medical care. We present a case of intra-axial pseudo-
progression following complementary proton radiation
therapy for a choroid plexus carcinoma in a child. We aim
to highlight radiological patterns of pseudoprogression after
proton beam therapy.
Case report A 6-year-old girl presented with choroid plexus
carcinoma, manifesting as change in behavior, tremor, and
balance disorder. Partial resection and chemotherapy were
performed. Complementary localized proton beam therapy
(54 Gy) was administered on the residual tumor. Eight
month follow-up MRI showed an abnormal, irregular, rim-
like enhancement in the pons and both temporal lobes
within the field of irradiation. These lesions had a low
cerebral blood volume (CBV) on perfusion MR imaging
and no restricted diffusion. However, the lesions were
hypermetabolic on O-(2-[18F]fluoroethyl)-L-tyrosine
(FET)-PET MRI. Follow-up MRI showed disappearance
of these lesions confirming the perfusion MR diagnosis
of pseudoprogression.
Conclusion Based on this case, radiological patterns of
pseudoprogression after proton beam therapy may be a
low CBV and no restricted diffusion. Lesions can be hyper-
metabolic on FET-PET imaging.
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Introduction
Proton beam therapy (PBT) is an emerging and promising
technique in neuro-oncology. Its fundamental principles
originate from particle physics research during World War
II, which led to the development of the early charged parti-
cle radiation therapy devices. The dosimetric characteristics
of protons allow the delivery of a high-dose radiation in a
limited area of the body [1].
Today, proton beam therapy has shown benefits in the
treatment of skull base tumors, pituitary adenomas, acoustic
neuromas, uveal melanoma, optic pathway gliomas, and
nasopharynx, paranasal sinuses, and spinal cord tumors [1].
Pseudoprogression is a rare complication of radiation
therapy consisting of new abnormal enhancing lesions
appearing often within 2 months after the completion of
radiochemotherapy and resolving spontaneously without
any treatment [2]. The incidence of pseudoprogression after
conventional photon therapy ranges from 5 to 24 % [3, 4].
Many previous studies have described pseudoprogression
after photon radiation therapy associated with temozolomide
chemotherapy for glioblastoma in adults. Subacute radiation
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injury in childhood gliomas treated by conventional ra-
diotherapy with or without chemotherapy has also been
described [5, 6], but only one case of pseudoprogression
after PBT for an intra-axial low-grade glioma in a teen-
ager has been reported so far [7]. The discrimination
between pseudoprogression and tumoral progression is a
radiological challenge and is of great importance for
further medical care.
We present a case of intra-axial pseudoprogression
following adjuvant proton radiation therapy for a cho-
roid plexus carcinoma. We aim to highlight radiological
patterns of pseudoprogression after proton beam therapy
in a pediatric case.
Case
A 6-year-old girl, with unremarkable medical and family
history, presented with behavior changes, tremor, and
balance disorder. Neurological and ophthalmological
examinations showed ataxia with a widened base, bilat-
eral papillary edema, decreased visual acuity (6/10 on
Snellen chart), and concentric visual field narrowing.
The initial brain MRI showed hydrocephalus and a large
and heterogeneous mass centered on the left lateral
ventricle (Fig. 1). This mass had a mixed tissular and
cystic composition with strong and heterogeneous en-
hancement after gadolinium administration. The lesion
was surrounded by parenchymal edema. The patient
underwent partial surgical resection of the lesion with
ventriculoperitoneal shunt placement. Cerebrospinal fluid
was free of any abnormality. The postoperative histo-
logical diagnosis was OMS grade III choroid plexus
carcinoma. A six-course chemotherapy according to the
protocol SIOP-CPT-2000, comprising carboplatin, etopo-
side, and vincristine, was administered from October to
July 2010. Proton beam radiation therapy (PBT) was
administered from March to May 2010 at a total dose
of 54 Gy on the residual tumor. She then received
temozolomide from October to December 2010 (1 month
and 11 days). The MRI follow-up (1.5 T) 8 months
after the start of radiation therapy showed the appear-
ance within the field of irradiation of abnormal hetero-
geneous enhancements in the pons and in both temporal
lobes with rim-like appearance. The lesions were hyper-
intense on T2W and FLAIR and hypointense on T1W
(Figs. 2 and 3). At this point, the differential diagnosis
was tumoral relapse versus pseudoprogression. An FDG
PET was performed and showed no hypermetabolism, in
particular within the abnormal enhancements. Then, a O-(2-
[18F]fluoroethyl)-L-tyrosine (FET)-PET MRI was performed
and showed a clear hypermetabolism in the lesions of the pons
and the left temporo-polar lobe orienting the diagnosis toward
tumor recurrence. PET acquisitions were performed on a
hybrid PET/MRI tomograph (Philips Ingenuity TF PET/MR
3 T). However, at MRI, there was no restricted diffusion on
diffusion-weighted imaging (DWI) and the lesions presented a
low cerebral blood volume (CBV) on the perfusion sequence,
indicating radiation-induced modifications.
The follow-up MRI at 11 and 29 months (Figs. 2 and 3)
showed disappearance of the lesions and confirmed the
diagnosis of pseudoprogression. The patient has kept post-
operation sequelae such as complete blindness as well as
frequent complex partial seizures controlled by medication.
The last follow-up MRI (26 months since the end of PBT)
showed no sign of relapse.
Discussion
To our knowledge this is the first reported case of intra-
axial pseudoprogression following proton beam therapy
of an extra-axial ventricular tumor in a pediatric patient.
In the presented case, diagnosis of pseudoprogression
was confirmed by the disappearance of lesions on
MRI follow-up.
Lesions were located bilaterally within the field of irra-
diation and appeared 8 months after the beginning of PBT.
The time of occurrence of pseudoprogression in our case is
delayed in comparison to the 2 months described in the
literature for adult gliomas treated by photon radiation ther-
apy and chemotherapy [2, 5, 8]. However it is concordant
with the only report of pseudoprogression after exclusive
PBT of a partially resected low-grade glioma in a teenager
by Meyzer and colleagues [7] who described a lapse of
6 months. Since our patient has been treated by chemother-
apy and PBT, and the case reported in the literature has been
Fig. 1 Brain MRI at presentation: axial T2-weighted image (a) and
T1-weighted image after gadolinium administration (b) showing a
large and heterogeneous mass centered on the left lateral ventricle,
with tissular and cystic components, strong and heterogeneous en-
hancement, mass effect, and perifocal parenchymal edema. Histologi-
cal diagnosis was OMS grade III choroid plexus carcinoma
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treated exclusively by PBT after surgery [7], we can assume
that the late appearance of pseudoprogression is related to
the use of PBT.
The lesions appeared hypointense on T1W and hyperin-
tense on T2W and FLAIR which is not specific. The rele-
vant MRI characteristics of these lesions are a low CBV on
the dynamic susceptibility contrast perfusion MR imaging
and absence of restricted diffusion on DWI. Our findings are
concordant with the literature, as Kang and colleagues have
shown that new lesions with restricted diffusion (low ADC
values) after radiosurgery for brain intra-axial metastasis are
more likely to be recurrent tumors than radiation-induced
injury [9]. Regarding CBV, our findings are in further
agreement with Essig and colleagues [10] who have shown
that a low CBV value is suggestive of tumor response in a
group of 18 patients with treated brain metastasis. Our
findings are also concordant with the study of Hoefnagels
and colleagues who showed that high relative CBV is sug-
gestive of tumor recurrence in a group of 20 tumor recur-
rences and 14 tumor necrosis following brain metastasis
treated by stereotaxic radiosurgery [11].
These studies are related to pseudoprogression after pho-
ton radiation therapy of intra-axial tumors and found similar
imaging characteristics in our case of extra-axial tumor
treated by proton radiation therapy in a child. So we can
suppose that pseudoprogression is a process which seems
unrelated to the type or location of the primary tumor, and
independent of the patient age, and its imaging patterns are a
low CBV with no restricted diffusion.
In our case, FET-PET imaging showed hypermetabolism
in two out of three lesions and was suggestive of tumor
progression, so it did not help to diagnose pseudoprogres-
sion. Many studies support that amino acid tracers, such as
FET and 11C-methionine, might be a valuable modality to
differentiate between tumor recurrence and pseudoprogres-
sion [12, 13]. In the latter studies, however, the primary
tumors were intra-axial gliomas treated by photon radiation
therapy, in opposition to our case describing a ventricular
extra-axial tumor treated by proton radiation therapy. In
agreement with our results, there are a few reports showing
PET positive findings in radiation necrosis lesions [14, 15].
The discrepancy of results regarding PET imaging findings
can possibly be explained by the different location of pri-
mary tumor and/or the radiation modality. Presumably, the
uptake intensity could support differential diagnosis, but
large series are required in order to validate a specific cutoff.
Analysis of CBV and diffusion-weighted imaging is
helpful in the differential diagnosis of relapse versus
radiation injury. Based on this case, it may be suggested
that low CBV and absence of restricted diffusion are
patterns of pseudoprogression, while FET-PET can be
positive in these cases.
Fig. 2 Follow-up MRI 8 months (a, b), 11 months (c), and 29 months
(d) after beginning of complementary proton beam irradiation. a Axial
T2-weighted showing an hyperintense lesion within the pons. b Axial
T1-weighted after gadolinium showing appearance of abnormal rim-
like enhancement (white arrow) with T2 hypersignal (a). The lesion
shows a low CBV (circle, a) and is hypermetabolic on FET-PET/MRI
(black arrow, b). Follow-up MRI at 11 and 29 months shows almost
disappearance of the lesion (white arrows, c, d) confirming the diag-
nosis of pseudoprogression
Fig. 3 Follow-up MRI 8 months (a–c), 11 months (d), and 29 months
(e) after beginning of complementary proton beam irradiation showing
appearance of abnormal rim-like enhancements on T1W after gadolin-
ium within the pons and both temporal lobes (arrows, a). The lesions
show a low CBV (circles, c) and two of them are hypermetabolic on
FET-PET/MRI (arrows, b). Follow-up MRI at 11 and 29 months
shows disappearance of temporal lesions and almost disappearance of
the pontine lesion (white arrows, d, e) confirming the diagnosis of
pseudoprogression
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